Novartis Adds Inflammation Drugs to Pipeline with Deal for IFM Tre
Less than a year after launching and only days after advancing its lead program into clinical trials, drug developer IFM Tre is in line to be acquired by Novartis. According to an agreement announced Monday, Novartis (NYSE: NVS) will acquire all of the outstanding stock of privately held IFM. The Basel, Switzerland-based pharmaceutical giant will […]